Načítá se...

Sunitinib for advanced renal cell cancer

Renal cell cancer has been refractory to drug therapy in the large majority of patients. Targeted agents including sunitinib have been intensively evaluated in renal cell cancer over the past 5 years. Sunitinib is an oral small molecule inhibitor of several targets including multiple tyrosine kinase...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autor: Coppin, Chris
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2008
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2727778/
https://ncbi.nlm.nih.gov/pubmed/19707433
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!